Format

Send to

Choose Destination
J Clin Lipidol. 2008 Oct;2(5):328-34. doi: 10.1016/j.jacl.2008.08.430. Epub 2008 Aug 15.

Ezetimibe-related myopathy: A systematic review.

Author information

1
Hospital of Saint Raphael, New Haven, CT, USA.

Abstract

Ezetimibe is a synthetic 2-azetidinone that inhibits the absorption of sterols, including cholesterol, in the intestine. It is used as monotherapy or in combination with statins to reduce low-density lipoprotein cholesterol (LDL-C). Although extremely well-tolerated, there are reports of myopathy associated with ezetimibe. We performed a PubMed search through April 2008 to identify English language articles examining ezetimibe safety as monotherapy or in combination with other lipid-lowering agents. The incidence of musculoskeletal disorders in clinical trials using ezetimibe alone or in combination with statins is identical to placebo or the statin alone, respectively. We identified only six case reports of possible ezetimibe-associated myopathy. We concluded that ezetimibe neither produces nor exacerbates statin myopathy except, possibly, in rare cases.

PMID:
21291757
DOI:
10.1016/j.jacl.2008.08.430

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center